Preclinical Anticancer Efficacy Studies on IBAL Formulations

Preliminary Evaluation Of ION-ZC1 As A Potential Anticancer Agent In Vitro

  • Completed in 2018 by Brooklyn College and The City University of New York, USA.
  • The ION-ZC1 solution is a responsive cytotoxic agent against:
    • Renal carcinoma cell line Caki-1 (IC50 36.12 ± 1.00 μM),
    • Triple-Negative Breast Cancer (MDA-MB-231),
    • and Melanoma cancer cell line A375 (IC50 95.20 ± 1.01 μM)
  • Highly selective when compared to the cytotoxicity of ION-ZC1 on control cells IMR-90 (IC50 142.6 ± 6.65 μM).
  • The ION-ZC1 solution induces apoptotic death in 92% of renal carcinoma cell line Caki-1 at dose IC50 36.12 ± 1.00 μM.

ION-ZC1 Topical Cream Anti-Tumor Efficacy Study Using A Syngeneic Mouse Melanoma Model (B16F0 – C57BL/6J), Study Design Of 30 Mice.

  • Completed in 2017 by the University of Debrecen, Hungary.
  • The main conclusion drawn from the study is that ION-ZC1 Topical Cream (17%) is:
    • Significantly efficacious against metastatic mouse melanoma as tested in a subcutaneous syngeneic mouse model (B16-F0 in C57BL/6J mice).
    • More efficacious than the Imiquimod Topical Cream (5%).
    • Tumor volumes recorded over the treatment period in the three groups support that tumor growth was slower as inhibited by ION-ZC1 Topical Cream (17%), and its effect was more pronounced as compared to the inhibitory effect of ALDARA (5% Imiquimod) Positive Control substance on tumor growth.
  • Conclusively, ION-ZC1 Topical Cream (17%) treatment extended survival time.

ION-ZC1 Anti-Tumor Efficacy Study By Intravenous Injection (Parenteral) Route, Using A Syngeneic Mouse Xenograft Model, More Specifically A Subcutaneous B16 Mouse Melanoma Model In C57BL/6J, Study Design Of 30 Mice.

  • Completed in 2016 by the University of Debrecen, Hungary.
  • Safety abnormalities compared to control tumor mice were not noted for any of the animals when necropsied at the conclusion of the 14-day observation period. As the most important results from the histopathological analysis, we can state that:
    • Tumors isolated from mice treated with various concentrations of ION-ZC1 IV injections show massive necrosis, which is not pronounced as much in tumors isolated from control tumor mice;
    • Blood vessels are much less frequent, less developed in the ION-ZC1 treated mice compared to control tumor mice.
    • ION-ZC1 injection results in spleen enlargement, which is remarkably (2-3 times) bigger in extent than that of the spleen of control (untreated) tumor mice, and consistent with ION-ZC1 inducing a strong anti-tumor immune response.
Preclinical Anticancer Efficacy Studies On IBAL Formulations
Sharing is caring




Copyright © 2024 All Rights Reserved ionic Alliance Group, Inc.